

## Post Covid 19 - Mucormycosis and Osteomyelitis of the Mandible- A Rare Case Report

Kanchan Shah<sup>1</sup>, Bhavana Valvi<sup>2\*</sup>, Prashant Pandilwar<sup>3</sup>, Suraj Parmar<sup>2</sup> and Wahab Shaikh<sup>1</sup>

<sup>1</sup>Associate Professor, Department of Oral and Maxillofacial Surgery, Government Dental College and Hospital, Aurangabad, Maharashtra, India

<sup>2</sup>Assistant Professor, Department of Oral and Maxillofacial Surgery, Government Dental College and Hospital, Nagpur, Maharashtra, India

<sup>3</sup>Professor and Head, Department of Oral and Maxillofacial Surgery, Government Dental College and Hospital, Aurangabad, Maharashtra, India

**\*Corresponding Author:** Bhavana Valvi, Assistant Professor, Department of Oral and Maxillofacial Surgery, Government Dental College and Hospital, Nagpur, Maharashtra, India.

**Received:** October 20, 2021

**Published:** December 09, 2021

© All rights are reserved by **Bhavana Valvi, et al.**

### Abstract

Post COVID Mucormycosis is declared epidemic in India after 2<sup>nd</sup> wave. Corticosteroids are widely use in the management of COVID 19, which causes tremendous immunosuppression and gives birth to various opportunistic bacterial and viral infections like, Mucormycosis which is a lethal or deadly infection which kills the patient or made the person physically handicapped. Mucormycosis is common in maxilla and rare in mandible. We are presenting a case report of a 55 years old male patient having post COVID Mucormycosis along with osteomyelitis of the mandible, the rarest form of the post COVID infection, which was managed surgically as well as with adjuvant medicinal management followed by post-operative prosthetic rehabilitation.

**Keyword:** Post COVID Mucormycosis; Osteomyelitis

### Introduction

Corona virus disease is caused due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It shows symptoms like chronic fever, cold, dry or wet cough, shortness of breath, anosmia, ageusia, diarrhoea, generalised malaise, acute cardiac injury and secondary infections [1]. SARS-CoV-2 infection has shown the increased risk of opportunistic fungal infections, like pulmonary aspergillosis and Mucormycosis with involvement of maxilla, maxillary sinus, nasal turbinate's, ethmoidal, frontal sinuses with massive destruction which ultimately leads to the death of person [2]. Association of fungal infection and COVID was found to be from 14.8 to 27% and 33% in severely ill patients of SARS-CoV-2 patients [3]. Mucormycosis of maxilla is more common than man-

dible. Mucormycosis was first described by Paultauf in 1885 and it is also known as zygomycosis, phycomycosis [4]. Mucormycosis is a life-threatening disease and commonly associated with immunosuppression and uncontrolled diabetes mellitus. During the second wave of COVID in India Mucormycosis was declared as epidemic. In the management of COVID widespread use of Corticosteroids was done which made immunosuppression of majority of the population, which has shown increased numbers of bacterial as well as fungal infections [5]. Even though the Post -COVID Mucormycosis of maxilla has become more common, Mucormycosis of mandible is a rare entity, and Mucormycosis along with osteomyelitis itself is a rarest form of the disease. Herein we report a case of Post COVID Mucormycosis and osteomyelitis of the mandible.

## Case Report


A 55 years old male patient reported to the department of oral and maxillofacial surgery with a chief complaint of active pus discharge from frontal region of the lower jaw. He was diagnosed with SARS COVID 2 (A nasopharyngeal swab was positive for SARS-CoV-2 by RT-PCR), three months back from the date of reporting. He was recently diagnosed with Type 2 Diabetes mellitus, when hospitalized for the management of COVID- 19. During the treatment days of COVID -19, he was under Steroids (intravenous Dexamethasone (6 mg once a day for 14 days), Inj Remdesivir ((200 mg on day 1 and 100 mg on days 2-5), 5 liter of Oxygen which was tapered gradually, higher antibiotics, Multivitamin, Tab zinc Thromboprophylaxis for venous thrombosis, and maintenance haemodialysis using Inj Enoxaparin followed by tab Aspirin 150 mg OD was prescribed, During the treatment days only, patient had noticed pus discharge from the lower jaw, but no inventory treatment was given. Patient has started treatment for Type 2 DM with oral hypoglycemic drugs and was able to control the blood sugar level within normal limits at present. The patient was a chronic smoker and due to COVID he has stopped his deleterious habit. At the time of admission, the respiratory rate was 27 breaths/minute, blood pressure was 110/70 mmHg, and heart rate of 86 beats/minute. The oxygen saturation was 98%. The patient was ectomorphic. Chest radiograph showed bilateral diffuse interstitial opacities. The haemoglobin was 10.8 g/dL, His random blood glucose was 144 mg/dL. After radiological and CT reports the HRCT Score for the patient was 14/23. Patient was having breathlessness in initial days of the COVID 2, was suffering from bodyach, cough, expectorations, fever. Sputum examination with Gram stain, stain for acid fast bacilli was negative, and fungal smear was positive suggestive of Rhizopus microspores. The in vitro antifungal susceptibility testing (AFST) of the isolate was performed. The minimum inhibitory concentrations (MICs) of the isolate were as follows: Amphotericin B, 0.5 lg/mL; Itraconazole, 0.03 lg/mL; Posaconazole, 2.0 lg/mL. His symptoms were improved and he was discharged after 62 days of long hospitalization. Patient had received Liposomal Amphotericin (3 mg/kg/day) on an outpatient basis for 21 days after discharge and was showing significant radiographic changes.

Patient when reported to us was having active pus discharge and completely exposed avascular denuded necrotic bone of the mandible from angle-to-angle region, with foul smell and mobility of all the mandibular teeth. The surrounding soft tissue was inflamed and vestibular obliteration was noted with mandible. Maxillary re-


gion was normal, maxillary sinus or any other sinusal involvement was not noted. Present clinical examination revealed the patient to be well oriented to time place and person, afebrile, and in severe pain on right and left side of face with paraesthesia of lower lip. Left submandibular nodes were palpable and tender. CBCT of mandible revealed an osteolytic lesion involving buccal and lingual cortices, loss of trabecular pattern of medullary bone, and multiple small air loculi with evidence of involucrum and sequestrum formation extending from left angle crossing midline and involving the Angle on the right side as well with no involvement of bilateral ramus, coronoid and condylar process of mandible. The lesion was involving whole mandible with no involvement of lower border of the mandible. Considering Clinico-radiographical features acute exacerbation of chronic osteomyelitis was made (Figure 1-4).

**Figure 1:** Preop exposed sequestrum of mandible.

**Figure 2:** Pre-op CBCT axial view showing bony destruction.




**Figure 3:** Pre-op 3 Dimensional CBCT view of mandible.




**Figure 4:** Sequestrectomy and saucerization on right side of mandible.

Incisional biopsy and KOH mount was performed. KOH mount report came negative for this patient. Patient was kept on antibiotics and analgesics. Swab collection was done and sent for culture and sensitivity test. Histopathological report came out as a Mucormycosis and osteomyelitis of the mandible. Hence patient was immediately shifted to the tab Posaconazole (300 mg BD on 1<sup>st</sup> day followed by 300 mg OD according to the AIIMS RISHIKESH India Guidelines for the management of Mucormycosis). For fabrication of obturator or prosthesis to be given to the patient post-operative-

ly, preoperatively alginate impression of the lower jaw was taken and cast models were fabricated. Under local anaesthesia full thickness mucoperiosteal flap was reflected from right to left angle region with crevicular incision, complete exposure of the underlying bone till lower border of mandible was performed. Extraction of all the mandibular teeth was performed. curettage and saucerization of the underlying bone were done. Intraoperative findings revealed completed necrosis of cortex and medullary bone with Gray and green discoloration of medullary region suggestive of Mucormycosis and osteomyelitis of the mandible (Figure 5,6).



**Figure 5:** Sequestrectomy and saucerization one left side of mandible.



**Figure 6:** Completely removed specimen.

Complete saucerization revealed necrosed mental and inferior alveolar neurovascular bundle. Complete excision was performed. After complete surgical debridement using betadine & hydrogen peroxide irrigation was done. Natural bleeding was achieved from surrounding bone before final closure. Final closure was performed using 3-0 vicryl absorbable suture material. Patient was encouraged to have oral liquid diet on same surgical day post operatively 2 hours after the surgery. Post-operative day was uneventful for the rest of the day. Patient was recalled after every alternate day for regular check-up and irrigation. Complete sequestrum after surgery was sent to histopathological examination which turned out to be the combination of Mucormycosis and osteomyelitis of the entire mandible (Figure 7,8).

**Figure 7:** Post-op Histopathological report with aseptate hyphae.

**Figure 8:** Post op Histopathological report with bony trabeculae with empty osteolytic lacunae with necrotic tissue.

Post-operatively after 15 days patient was sent for the prosthetic rehabilitation, Obturator fabrication was done. At present patient is under regular follow up and there is no recurrence noted till date.

## Discussion and Conclusion

Fungi are always considered more infectious and harmful to human body than bacterial infections [4]. Fungi are avirulent and becomes pathogenic when host resistance decreases or immunosuppression takes place. Mucormycosis belongs to Mucorales a subtype of zygomycetes and is associated with tissue necrosis as its angiotrophic in nature and lethal fungi. Invasive Mucormycosis causes tissue necrosis due to incursion of blood vessels, ensuing thrombosis. Hyperglycaemia, immunosuppression provides favourable environment for the growth of *Rhizopus oryzae* fungi responsible for Rhino-Orbital Mucormycosis as in uncontrolled diabetic patients, diabetic keto-reductase enzyme allows fungi to use more ketone bodies for their growth and proliferation [6]. COVID 19 patients are treated with high dosages of corticosteroids which causes increased blood sugar level, and COVID 19 is responsible for coagulation of blood, incursion of blood vessels and thrombosis leads to decreased or no blood supply to the jaw bones [7]. It has been established that diabetic ketoacidosis momentarily disrupts the ability of transferrin to bind iron and this alteration permits the growth of *Rhizopus oryzae* [8]. Majority of the Mucormycosis cases are found in maxilla than mandible. Mucormycosis along with osteomyelitis is the rarest variety encountered in literature. During 2<sup>nd</sup> wave of COVID 19, Post COVID Mucormycosis was declared as epidemic and patients cured from COVID died due to Rhino-Orbital Mucormycosis at an early age. Management of such post COVID Mucormycosis should be early diagnosis, reversal of the underlying cause, controlling blood sugar level, surgical debridement of the infected bone and medicinal management includes Antifungal drugs like Inj Amphotericin B Deoxycholate with maximum tolerated dose being, 1 to 1.5 mg/kg/day. for 21 days dose depending on patients' body weight, Tab/syrup Posaconazole 300 mg BD, Day 1 followed by 300 mg OD for 2 weeks [6]. Hyperbaric oxygen therapy should also be considered which increases oxygen pressure at infected or necrosed bone region and increases neutrophil capacity for phagocytosis as well as causes Neoangiogenesis and also it reverses Lactic acidosis and hence increases the rapid recovery hence 100% oxygen saturation for about 90 - 120 minute with pressure of about 2.0 to 2.5 atmospheric pressure is recommended [10]. Patients diagnosed with COVID 19 should be timely

evaluated for the blood coagulation profile, all the patients should keep on anticoagulant as in COVID 19 patient thrombosis is the main reason which hampers the blood supply to the jaw bone and other body parts as well. Hence all routine blood investigations like BT, CT, INR, D-DIMER all should be evaluated. Oral prophylaxis should be done routinely along with use of Betadine mouth wash should made compulsory for all the patients [11]. The development of Mucormycosis in COVID 19 patients is significantly found in association with use of cortico-steroids which leads to hyperglycaemia. Acute respiratory distress syndrome due to COVID needs timely monitoring via diagnostic imaging and testing. Patients kept for prolonged intubation are not in condition to maintain a good oral hygiene and hence makes the environment suitable for opportunistic growth of the fungi [12]. Hence judicious use of steroids is indicated. Use of Tocilizumab should be avoided as many studies has shown association of Tocilizumab with Mucormycosis in COVID 19 patients [7]. Patients with COVID 19 are found to be associated with aspergillosis, candidiasis as well as Mucormycosis and it can show multi-organ involvement as well. Hence high degree of clinical suspicion is required for the early diagnosis and management of the COVID 19 associated Mucormycosis [13,14].

## Bibliography

1. Sharma S., et al. "Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum". *The Journal of Laryngology and Otology* 135.5 (2021): 442-447.
2. Bhatt Kinal., et al. "High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections". *Discoveries* 9.1 (2021).
3. Dilek A., et al. "COVID-19-associated mucormycosis: Case report and systematic review". *Travel Medicine and Infectious Disease* 26 (2021): 102148.
4. A Paultauf. "Mycosismucorina". *Virchow's Archiv fur Pathologische Anatomie und Physiologie und fur klinische Medizin* 102 (1985): 543-564.
5. Arastehfar Amir., et al. "COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment". *Journal of Fungi* 6.2 (2020): 91.
6. Rao Eswar., et al. (2015).
7. Kimmig Lucas M., et al. "Il-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections". *Frontiers in Medicine* 7 (2020): 689.
8. Artis William M., et al. "A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis transferrin and iron availability". *Diabetes* 31.12 (1982): 1109-1114.
9. Khudyakov Aleksandr., et al. "A Rare Indolent Course of Rhinocerebral Mucormycosis". *Case Reports in Infectious Diseases* 2021 (2021).
10. Thom Stephen R. "Analytic reviews: hyperbaric oxygen therapy". *Journal of Intensive Care Medicine* 4.2 (1989): 58-74.
11. Oswal Nitin Prakash., et al. "Mucormycosis of mandible with unfavorable outcome". *Case Reports in Dentistry* 2012 (2012).
12. Pasero Daniela., et al. "A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis". *Infection* 49.5 (2021): 1055-1060.
13. Kimmig Lucas M., et al. "Il-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections". *Frontiers in medicine* 7 (2020): 689.
14. Garg Deepak., et al. "Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature". *Mycopathologia* (2021): 1-10.
15. Muthu Valliappan., et al. "The reversed halo sign and the bronchus sign: the eyes see only what the mind knows". *Annals of the American Thoracic Society* 16.9 (2019): 1203-1203.

### Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

Website: [www.actascientific.com/](http://www.actascientific.com/)

Submit Article: [www.actascientific.com/submission.php](http://www.actascientific.com/submission.php)

Email us: [editor@actascientific.com](mailto:editor@actascientific.com)

Contact us: +91 9182824667